NCT00370162
Completed
Phase 3
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata New Fragrance
ConditionsHygiene
Drugslactoserum
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Hygiene
- Sponsor
- Sanofi
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Adverse Events and its association with the drug in study
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to demonstrate the safety of the gynaecological formulation in normal and usual usage condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Integral skin in the tested region
Exclusion Criteria
- •Pregnancy or breastfeeding women
- •Use of antiinflammatory or immunosuppression drugs
- •Topical medication use at the tested region
- •Active cutaneous gynaecological disease
- •Personal history of allergic disease at the area to be treated
- •Allergic or atopic history
Outcomes
Primary Outcomes
Adverse Events and its association with the drug in study
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Acceptability Dermacyd Wipes - Lactoserum - HygieneHygieneNCT00397527Sanofi30
Completed
Phase 4
Acceptability Lactoserum (Dermacyd Delicata - New Fragrance)HygieneNCT00497783Sanofi30
Completed
Phase 4
Acceptability of Lactacyd FeminaHygieneNCT00712868Sanofi559
Completed
Phase 4
Dermacyd Infantile - Acceptability.HygieneNCT00881270Sanofi31
Completed
Phase 3
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet FlowerHygieneNCT00663273Sanofi30